<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601586</url>
  </required_header>
  <id_info>
    <org_study_id>14 7440 01</org_study_id>
    <nct_id>NCT02601586</nct_id>
  </id_info>
  <brief_title>Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease</brief_title>
  <acronym>OXYDOPA</acronym>
  <official_title>Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in three parallel groups receiving oxycodone, levodopa or
      placebo, administered as an add-on therapy, in addition to the usual antiparkinsonian
      treatment. As this study focuses on chronic central neuropathic pain caused by PD, the
      effects of study treatments will be evaluated after a 10-week treatment period
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment period (11 weeks) will be divided into three periods:

        1. A titration phase of two weeks, during which of the doses of the treatments will be
           gradually increased in three steps:

           Level 1 (from D1 to D5):

             -  Oxycodone: 10 mg PR/day bid (5 mg PR/5 mg PR)

             -  Levodopa: 100 mg/day bid (50 mg/50 mg)

           Level 2 (from D6 to D10):

             -  Oxycodone: 20 mg PR/day tid (10 mg/0 mg/10 mg)

             -  Levodopa: 150 mg/day tid (50 mg/50 mg/50 mg)

           Level 3 (from D11to D15):

             -  Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)

             -  Levodopa: 200 mg/day tid (100 mg/50 mg/50 mg)

        2. A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
           The study treatment will be administered as an add-on therapy, with the usual
           antiparkinsonian treatment. If patients have side effects at the level 3 dose, a return
           to the level 2 dose will be authorized.

        3. A withdrawal period: The dose of the study treatment will gradually be reduced, over an
           eight-day period:

      For patients treated with the level 3 dose for 8 weeks: decrease to the level 2 dose over the
      first 3 days (from D72 to D74) ; then a decrease to the level 1 dose over the next 3 days
      (from D75 to D77). The treatment will be stopped completely on D78. The last visit will take
      place on D79, 2 days after the end of treatment.

      For patients treated with the level 2 dose: decrease to the level 1 dose over the first 3
      days (from D72 to D74), with stopping of the treatment on D75. The last visit will take place
      on D79, 5 days after the end of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average pain intensity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in average pain rated on visual analog scale (VAS) intensity between baseline and after 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal pain intensity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of maximal pain intensity over the preceding week rated on the VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional impact of pain&quot; of the Brief Pain Inventory (BPI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Symptoms Inventory (NPSI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>McGill pain questionnaire (SFMPQ)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression and anxiety: the Hospital Depression and Anxiety (HAD) scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apathy: the Lille Apathy Rating Scale (LARS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue : the Parkinson fatigue scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep : the Pittsburgh sleep quality index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor assessment and motor fluctuations: MDS UPDRS (MDS Movement Disorder Society - UPDRS Unified Parkinson Disease Rating Scale)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: Parkinson's Disease Questionnaire 39 items (PDQ-39)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in scores between Day 0 and Day 71(Day 71= 8 weeks of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen consumption reported in diary</measure>
    <time_frame>8 weeks</time_frame>
    <description>number of pills or capsules reported in patients diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 5, Day 10, Day 15, Day 43, Day 71, Day 79</time_frame>
    <description>Adverse events, evaluated with an open-ended questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Resting-state brain network (3T fMRI)</measure>
    <time_frame>Day 0 /Day 71(Day 71= 8 weeks of treatment)</time_frame>
    <description>changes in resting-state cerebral networks between Day 0 and Day 71, as assessed by 3T fMRI.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>PR oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A titration phase of two weeks, in three steps:
Level 1 (from D1 to D5):
Oxycodone : 10 mg PR/day bid (5 mg PR/5 mg PR)
Levodopa placebo 100 mg/day bid (50 mg/50 mg)
Level 2 (from D6 to D10):
Oxycodone : 20 mg PR/day tid (10 mg/0 mg/10 mg)
Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)
Level 3 (from D11to D15):
Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)
Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)
A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
A withdrawal period:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levodopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A titration phase of two weeks, in three steps:
Level 1 (from D1 to D5):
Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)
Levodopa 100 mg/day bid (50 mg/50 mg)
Level 2 (from D6 to D10):
Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)
Levodopa : 150 mg/day tid (50 mg/50 mg/50 mg)
Level 3 (from D11to D15):
Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)
Levodopa : 200 mg/day tid (100 mg/50 mg/50 mg)
A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
A withdrawal period:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A titration phase of two weeks, in three steps:
Level 1 (from D1 to D5):
Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)
Levodopa placebo 100 mg/day bid (50 mg/50 mg)
Level 2 (from D6 to D10):
Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)
Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)
Level 3 (from D11to D15):
Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)
Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)
A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
A withdrawal period:</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR Oxycodone</intervention_name>
    <description>PR Oxycodone</description>
    <arm_group_label>PR oxycodone</arm_group_label>
    <other_name>PR Oxycontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
    <description>Levodopa</description>
    <arm_group_label>levodopa</arm_group_label>
    <other_name>Modopar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone Placebo</intervention_name>
    <description>Placebo of PR Oxycodone</description>
    <arm_group_label>levodopa</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa placebo</intervention_name>
    <arm_group_label>PR oxycodone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Parkinson's disease according to the UKPDSBB (United Kingdom Parkinson's
             Disease Society Brain Bank) criteria

          -  Patients suffering from chronic pain (lasting for more than 3 months)

          -  Patients suffering from central neuropathic pain caused by PD,

          -  Patients with a PD-related central neuropathic pain intensity of at least 3 points on
             the VAS (average intensity over the last month),

          -  Patients with both types of pain (neuropathic and nociceptive) will be included if the
             neuropathic pain predominates

          -  Patients treated with a stable regimen of dopaminergic drugs (levodopa and/or dopamine
             agonists) for at least 4 weeks before the study dan throughout the study

          -  Patients with a stable step 1 analgesic (NSAIDS, acetaminophen) or coanalgesic
             (antidepressants, antiepileptic) treatment for at least 4 weeks before the study and
             throughout the study

        Exclusion Criteria:

          -  Patients suffering from another parkinsonian syndrome

          -  De Novo patients (patients never before treated with dopaminergic drugs)

          -  Patients with intercurrent acute pain

          -  Patients suffering from a chronic disease causing pain (rheumatoid arthritis,
             ankylosing spondylitis, diabetic neuropathy, cancer etc.)

          -  Patients treated with neuroleptics

          -  Patients treated by deep brain stimulation

          -  Patients with clinically detectable behavioural disorders and addiction

          -  Patients with disabling dyskinesias

          -  Patients with painful restless legs syndrome

          -  Patients with cognitive impairment (MMS &lt; 25) or unable to complete the various scales
             used in the study

          -  Hypersensitivity to oxycodone, levodopa, benserazide or a combination of these drugs

          -  Patients treated with opioid drugs (step 2 and 3)

          -  Patients treated with non-selective monoamine oxidase inhibitors (MAOI)

          -  Patients with severe hepatocellular insufficiency

          -  Patients with uncontrolled cardiovascular and pulmonary diseases

          -  Persistent constipation that has already resulted in a subocclusive state

          -  Patients treated with antiemetic neuroleptics

          -  Patients with angle-closure glaucoma

        Exclusion criteria relating to MRI:

          -  Patients with claustrophobia

          -  Patients with a hearing aid, cardiac prosthesis, pacemaker, surgical clip

          -  Patients refusing to be informed of abnormalities are detected on MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine BREFEL-COURBON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU TOULOUSE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire THALAMAS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU TOULOUSE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Elise LLAU</last_name>
    <phone>0561778771</phone>
    <phone_ext>+33</phone_ext>
    <email>llau.me@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charline DAGUZAN</last_name>
    <phone>0561778490</phone>
    <phone_ext>+33</phone_ext>
    <email>daguzan.c@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of Aix-en-Provence</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viallet, MD</last_name>
      <email>fviallet@ch-aix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystkowiak, MD</last_name>
      <email>krystkowiak.pierre@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tison, MD</last_name>
      <email>francois.tison@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Durif , MD</last_name>
      <email>fdurif@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>REMY, MD</last_name>
      <email>neuro-philippe.remy@hmn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Defevbre, MD</last_name>
      <email>Luc.DEFEBVRE@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torny</last_name>
      <email>frederic.torny@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azulay</last_name>
      <email>Jean-philippe.AZULAY@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rouaud, MD</last_name>
      <email>Tiphaine.Rouaud@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corvol</last_name>
      <email>jean-christophe.corvol@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houeto, MD</last_name>
      <email>jean-luc.houeto@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drapier, MD</last_name>
      <email>Sophie.Drapier@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maltête, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Tranchant, MD</last_name>
      <email>Christine.Tranchant@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine BREFEL-COURBON, MD</last_name>
      <email>christine.brefel-courbon@univ-tlse3.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

